Indicatie: | MM Participants with Relapsed or Refractory Myeloma who Have Received 1-4 Prior Lines of Therapy Including an AntiCD38 Antibody and Lenalidomide |
Studie: | MonumenTAL-6 |
| A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (TalP), Talquetamab in Combination with Teclistamab (TalTec), and Investigators Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1-4 Prior Lines of Therapy Including an AntiCD38 Antibody and Lenalidomide |
Open in: | HAGA |
Contact: | researchhematologie@hagaziekenhuis.nl |
Status: | OPEN |
|
Indicatie: | DLBCL (NOS), High-grade B-cell lymphoma (MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (DHL/THL) and FL3B, T-cell/histocyte rich B-cell lymphoma, Primary mediastinal B-cell lymphoma, transformed lymphoma (transformed follicular) and R/R after at least 2 lines of systemic therapy.
Age >17 jr |
Studie: | HOVON161 |
| A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma |
Open in: | LUMC |
Contact: | J.S.P.Vermaat@lumc.nl |
Status: | OPEN |
|
Indicatie: | Autoimmune Hemolytic Anemia |
Studie: | MOM-M281-006 Energy |
| Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension |
Open in: | HAGA |
Contact: | researchhematologie@hagaziekenhuis.nl |
Status: | OPEN |
|
Indicatie: | rrDLBCL |
Studie: | LOTIS-5 ADCT402-311 |
| A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5).
|
Open in: | HAGA |
Contact: | researchhematologie@hagaziekenhuis.nl |
Status: | OPEN |
|
Indicatie: | Relapsed or Refractory MM |
Studie: | Excaliber (CC-220-MM-002) |
| A Ph III, Randomized, Multicnenter, Ope-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberdD) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) IN Subjects with Relapsed or REfractroy MM (RRMM) |
Open in: | HAGA |
Contact: | researchhematologie@hagaziekenhuis.nl |
Status: | OPEN |
|
Indicatie: | Relapsed or Refractory HL
Leeftijd: ≥ 18 jr |
Studie: | HOVON 164 Tigerr |
| Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Response (TIGERR-HL) |
Open in: | HAGA |
Contact: | researchhematologie@hagaziekenhuis.nl |
Status: | OPEN |
|
Indicatie: | DLBCL
leeftijd 18-80 jr |
Studie: | M20-621 |
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in
Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell
Lymphoma (DLBCL) (EPCORE DLBCL-2) |
Open in: | HMC
LUMC |
Contact: | l.te.boome@haaglandenmc.nl; j.s.p.vermaat@lumc.nl |
Status: | OPEN |
|
Indicatie: | Classic FL (prev. Gr 1-3a) stage II, III, IV, R/R
Leeftijd ≥ 18 jaar |
Studie: | M20-638 |
| A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) |
Open in: | LUMC |
Contact: | J.S.P.Vermaat@lumc.nl |
Status: | OPEN |
|
Indicatie: | *DLBCL, NOS
*High-grade BCL + MYC and BCL-2 and/or BCL-6 translocations
*FL grade 3B
Leeftijd ≥ 18 jaar |
Studie: | M22-132 |
| Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in
Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma |
Open in: | LUMC |
Contact: | J.S.P.Vermaat@lumc.nl |
Status: | OPEN |
|
Indicatie: | R/R B-cell non-Hodgkin lymphoma (DLBCL, FL, MZL, MCL); leeftijd ≥18 jaar |
Studie: | CP0201-NHL Atalanta-1 |
| A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma |
Open in: | LUMC |
Contact: | J.S.P.Vermaat@lumc.nl |
Status: | OPEN |
|